Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025—
BRIDGEWATER, N.J., Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. The FDA provided this update in its Day 74 communication to Insmed.
"We are very pleased with our ongoing communications with the FDA about the NDA for brensocatib," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "We are committed to working closely with the agency to successfully complete the review and potentially bring forward this much-needed treatment for patients with bronchiectasis."
The FDA had previously granted Priority Review to Insmed's NDA for brensocatib and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act (PDUFA). This NDA is based on data from the landmark ASPEN study, the largest Phase 3 study ever conducted in patients with bronchiectasis. Brensocatib has the potential to become the first and only approved treatment for bronchiectasis and the first in a new class of medicines called dipeptidyl peptidase 1 (DPP1) inhibitors for the treatment of neutrophil-mediated diseases.
About Bronchiectasis
Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. Today, approximately 500,000 patients in the U.S., 600,000 patients in the EU5 (France, Germany, Italy, Spain, and UK), and 150,000 patients in Japan have been diagnosed with bronchiectasis, and there are currently no approved therapies specifically targeting bronchiectasis in these regions.
About Brensocatib
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis without nasal polyps, hidradenitis suppurativa, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.
Forward-looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.
The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risk that the full data set from the ASPEN study or data generated in further clinical trials of brensocatib will not be consistent with the topline results of the ASPEN study or any additional results of the ASPEN study; failure to obtain, or delays in obtaining, regulatory approvals for brensocatib in the U.S., Europe or Japan; failure to successfully commercialize brensocatib, if approved by applicable regulatory authorities, in the U.S., Europe or Japan, or to maintain U.S., European or Japanese approval for brensocatib once approved; uncertainties in the degree of market acceptance of brensocatib by physicians, patients, third-party payors and others in the healthcare community; inaccuracies in the Company's estimates of the size of the potential markets for brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; inability of the Company, Esteve Química, S.A., Thermo Fisher Scientific, Inc. or the Company's other third-party manufacturers to comply with regulatory requirements related to brensocatib; the Company's inability to obtain adequate reimbursement from government or third-party payors for brensocatib or acceptable prices for brensocatib; development of unexpected safety or efficacy concerns related to brensocatib; failure to obtain regulatory approval for potential future brensocatib indications; restrictions or other obligations imposed on us by agreements related to brensocatib, including our license agreement with AstraZeneca AB, and failure to comply with our obligations under such agreements; failure to successfully conduct future clinical trials for brensocatib, including due to the Company's potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of brensocatib for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business or agreements with the Company; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; the cost and potential reputational damage resulting from litigation to which the Company may become a party, including product liability claims; changes in laws and regulations applicable to the Company's business and failure to comply with such laws and regulations; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; and inability to repay the Company's existing indebtedness and uncertainties with respect to the Company's need and ability to access future capital.
The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Company filings with the Securities and Exchange Commission (SEC).
The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contact:
Bryan DunnVice President, Investor Relations(646) 812-4030bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.Director, Investor Relations(917) 936-8430michael.morabito@insmed.com
Gianna De PalmaManager, Investor Relations(973) 886-2236gianna.depalma@insmed.com
Media:Mandy FaheyVice President, Corporate Communications(732) 718-3621amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-announces-that-fda-does-not-currently-plan-to-hold-advisory-committee-meeting-to-discuss-new-drug-application-for-brensocatib-in-patients-with-bronchiectasis-302382854.html
SOURCE Insmed Incorporated
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
COVID Crusader Writes Open Letter To RFK Jr On mRNA
A prominent group of health activists is threatening a political revolt against HHS Secretary Robert F. Kennedy Jr. over what they call a betrayal of their movement's central cause. In a blistering open letter dated June 4, COVID crusader Dr. Mary Talley Bowden and several allies from the MAHA (Make America Healthy Again) movement — a grassroots coalition of vaccine-critical and medical freedom activists — accused Kennedy and FDA Commissioner Dr. Marty Makary of watering down policies related to the controversial mRNA vaccine platform, especially in guidance affecting children and pregnant women. 'We did not fight for you to be in positions of leadership so that our clearly stated policy goals would suffer a 'bait and switch,'' Bowden wrote, warning Kennedy that MAHA voters 'can walk away' if their demands are not met. The letter criticizes recent CDC and FDA policy changes, calling them deceptive and insufficient, and claims the administration is engaging in 'linguistic misdirections' to hide the continued recommendation of mRNA shots for vulnerable populations. The MAHA letter insists the mRNA platform — particularly COVID vaccines — should be pulled from the market entirely, citing adverse event data and peer-reviewed studies. It demands sweeping reforms: a full ban on mRNA technologies, repeal of the PREP Act, elimination of vaccine-related conflicts of interest in federal agencies, and an end to direct-to-consumer pharmaceutical advertising. The signatories include author Naomi Wolf, podcaster Shannon Joy, and several other activists who rose to prominence during the COVID-19 pandemic by challenging government vaccine narratives. The backlash comes amid growing scrutiny of RFK Jr.'s recent actions as HHS secretary. Once one the nation's most vocal mRNA vaccine skeptic, Kennedy has walked a careful line in office, telling Congress in May that his personal views on vaccines are 'irrelevant' and vowing not to make sudden changes to CDC policy. 'I don't think people should be taking medical advice from me,' Kennedy told lawmakers, as reported by The Hill on June 2. Still, his critics on both sides see Kennedy's recent moves as consequential. Late last month, he released a 58-second video on X stating that COVID vaccines for healthy children and healthy pregnant women had been removed from the CDC's immunization schedule — a declaration Bowden and others say was misleading. Indeed, as The Hill previously reported, the CDC quietly changed its guidance to say healthy children may receive the COVID vaccine after consultation with a healthcare provider, while maintaining stronger recommendations for other vulnerable categories. For pregnant women, the recommendation was similarly softened but not eliminated, and pregnancy remains classified by the FDA as a high-risk health condition, allowing continued vaccine use under certain circumstances. Bowden's letter zeroes in on this ambiguity, arguing that wordplay is being used to sustain vaccine availability under the appearance of reform. 'Pregnant women have not been made any safer by your wordplay,' she writes, warning that MAHA activists are prepared to run their own candidates in upcoming elections if their demands are ignored. The political threat underscores the friction between Kennedy and the movement that once celebrated his nomination. While Kennedy has taken steps to reshape HHS in ways consistent with his skepticism — including canceling hundreds of millions of dollars in funding for Moderna's mRNA flu vaccine— his first few months of actions have not thus far rendered the swift action that some would have hoped. Former CDC acting director Dr. Richard Besser and other public health experts have voiced alarm at Kennedy's willingness to circumvent the CDC's vaccine advisory panel, which has traditionally guided immunization policy through public, evidence-based deliberation. 'We're seeing a total side-stepping of the nation's leading public health agency,' Besser told The Hill. The vaccine panel has not yet weighed in on the updated COVID shot guidance. Its next meeting is scheduled for late June, and observers expect tense debate over whether Kennedy's changes represent science-based reform or political overreach. In the meantime, Bowden's warning reflects the fragile coalition Kennedy is attempting to hold together. The MAHA movement — built in part from disaffected MAGA voters, vaccine skeptics, and parents concerned about government overreach — played a pivotal role in rallying support for Kennedy's confirmation and the broader medical freedom agenda. Now, its leaders are openly questioning whether Kennedy's tenure will deliver the systemic change they demand — or whether they were simply used to fuel a political ascent. 'MAHA is not the possession of Secretary Kennedy,' Bowden wrote. 'It is the voice of millions of desperate parents… and their activism will outlast any administration.' The Dallas Express reached out to HHS but did not immediately receive a response. Kennedy previously spoke to The Dallas Express about a lawsuit Bowden brought against the FDA for misleading the public about using ivermectin for the treatment of COVID-19 during his presidential campaign in 2024 and just after the FDA settled the case. 'All three of the principal health agencies [CDC, NIH, FDA] suffer from agency capture,' Kennedy said. 'I would say 50% of the FDA's budget is from pharmaceutical companies. NIH scientists are allowed to collect royalties on drugs that they regulate –– which is clearly a conflict of interest. CDC … has devolved into an agency that primarily promotes the mercantile interests of the pharmaceutical companies.' He told DX that the agencies are overly influenced by perverse incentives from the pharmaceutical industry and added, 'I will change those incentives and unravel the culture of corruption that now has turned these agencies against public health.'
Yahoo
12 minutes ago
- Yahoo
Amazon Pledges $20 Billion for Pennsylvania Data Centers
Amazon (NASDAQ:AMZN) is set to pour $20 billion into Pennsylvania for new AWS data-center campuses, fueling its AI and cloud ambitions while creating over 1,250 high-skilled jobs. Warning! GuruFocus has detected 2 Warning Sign with AMZN. The first two innovation hubs will rise in Luzerne and Bucks countiesSalem and Falls townships respectivelywith additional sites under review, Governor Josh Shapiro said. Since 2010, Amazon has plowed more than $26 billion into Pennsylvania infrastructure and payroll, generating 27,000 direct jobs. This latest boost will also support thousands of roles across the AWS data-center supply chain and is paired with a $250,000 Amazon Northeastern Pennsylvania Community Fund for STEM, sustainability, digital skills, culture and health grants. One Luzerne facility sits alongside the Susquehanna nuclear plant owned by Talen Energy; Amazon's $650 million purchase of that site to tap up to 960 MW has drawn FERC scrutiny over grid-fairness and power allocation issuesthe first such case before the commission. Amazon and Talen must address concerns that shifting power to data centers could disadvantage other consumers and skirt grid-use fees. Amazon didn't immediately comment on FERC's review. Tech peers like Microsoft (NASDAQ:MSFT) and Meta (NASDAQ:META) are also investing billions in AI-ready data centers, but Amazon's Pennsylvania commitment stands out for its scale and local job impact. Why It Matters: Amazon's massive spend underscores the critical role of hyperscale data centers in supporting AI growth and confirms Pennsylvania's emergence as a cloud-computing hub. This article first appeared on GuruFocus.
Yahoo
18 minutes ago
- Yahoo
APhA withholds endorsement of ACIP Adult Immunization Schedule
WASHINGTON, June 9, 2025 /PRNewswire/ -- APhA is the only pharmacy representative among several professional organizations that reviews and evaluates the ACIP Adult Immunization Schedule annually. Recently, there have been several updates to the COVID-19 vaccine recommendations made by the Department of Health & Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). These changes include removing the recommendation for people who are pregnant to receive the COVID-19 vaccine. Studies have shown that people who are pregnant or were recently pregnant are: More likely to get very sick from COVID-19 compared to those who are not. More likely to need hospitalization, intensive care, or the use of a ventilator or special equipment to breathe if they do get sick from COVID-19. At increased risk of complications that can affect pregnancy and the baby, including preterm birth or stillbirth. COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men. APhA's stance is that pregnancy is a high-risk condition; therefore, people who are pregnant should be recommended to receive the COVID-19 vaccine. The May 2025 updates to the COVID-19 vaccine recommendations do not appear to be based on the scientific evidence provided over the past few years. Considering this recent change, APhA has decided to withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025. This decision was proposed by a group of APhA members who are immunization subject matter experts and approved by the APhA Board of Trustees. APhA requests, and is hopeful, that future updates of the Adult Immunization Schedule be based on scientific evidence and would reconsider its endorsement upon the schedule being discussed and recommended by ACIP. View original content to download multimedia: SOURCE American Pharmacists Association